Multiple Sclerosis Vlog: Calf Cramps Worsen Thinking and Memory!?
Click HERE to Subscribe for the MS Beacon Newsletter WATCH THIS VIDEO, then please share with others by giving them…
Primary Progressive Multiple Sclerosis (PPMS)
Click HERE to Subscribe for the MS Beacon Newsletter “““““““““““““““““““““““““““““““““`Want to see the MS Views and News MS Learning Channel on YouTube? …
Stuart Schlossman
Launching a new MS drug responsibly, during Covid-19
Click HERE to Subscribe for the MS Beacon Newsletter As a company, Novartis had to ask themselves what launching a…
Stuart Schlossman
What is Myelin?
Click HERE to Subscribe for the MS Beacon Newsletter Overview Neurons are the structures in the nervous system that allow…
Stuart Schlossman
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis
Click HERE to Subscribe for the MS Beacon Newsletter East Hanover, August 20, 2020 — Novartis today announced that…
Stuart Schlossman
CoViMS Registry for those with MS, and other CNS demyelinating diseases (Neuromyelitis Optica Spectrum Disease, or MOG antibody disease) who have developed COVID-19
*** This COViMS (COVID-19 Infections in MS & Related Diseases) is a joint effort of the National MS Society, the…
Stuart Schlossman
Mylan Brings Critical Access to the Multiple Sclerosis Community by Launching a More Affordable Treatment Option Through a First Generic to Tecfidera®
Click HERE to Subscribe for the MS Beacon Newsletter HERTFORDSHIRE, England and PITTSBURGH, Aug. 19, 2020 /PRNewswire/ — Mylan N.V. (NASDAQ: MYL) today announced the launch of the…
Stuart Schlossman
Your Brain Fog May Be an Anxiety Symptom — Here’s How to Deal with It
Click HERE to Subscribe for the MS Beacon Newsletter Brain fog describes a mental fuzziness or lack of clarity. When…
Stuart Schlossman
Relationships and Intimacy: When MS Gets In the Way
Click HERE to Subscribe for the MS Beacon Newsletter By: Kathleen Healey, NP, PhD and Meghan Beier, PhD Up to…
Stuart Schlossman
Rituximab More Effective Than Gilenya, Tecfidera, and Comparable to Tysabri, Study Finds
AUGUST 11, 2020 BY MARTA FIGUEIREDO Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl…
Stuart Schlossman
